secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2022-02-16T23:59:59+00:00
Accession:  0001654954-22-001759
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 4.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zivo Bioscience appoints BDO as auditor and finalizes CEO John Payne's employment contract
--------------------------------------------------------------------------------

- Appointed BDO USA, LLP as independent auditor effective February 10, 2022, replacing resigned auditor Wolinetz, Lafazan & Company.
- CEO John Payne's contract provides $400k annual salary, bonus up to 125% of salary, and annual equity awards valued at $400k.
- ZIVO 2021 Plan reserves 1,000,000 shares with automatic annual increase of 5% of outstanding shares through 2031.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422001759/0001654954-22-001759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422001759/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-001759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer